Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track DRUG with free AI briefings, catalyst countdowns, and dilution alerts.

DRUG · Bright Minds Biosciences Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$307.8M Cash on Hand
149.7mo Cash Runway
10.5% Short Interest
$107.44 Analyst Target (7)
Follow DRUG by email Get an email when DRUG reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about DRUG, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Technetium Tc-99m Albumin Aggregated Carcinoma Phase 4 · NCT05848947 Completed
ASI-02 Right-To-Left Shunt Phase 3 · NCT06938347 Recruiting
BMB-101 Absence Epilepsy Phase 2 · NCT06401538 Recruiting
BC-101 Nasolabial Fold Wrinkles Phase 1 · NCT05162326 Not yet recruiting
Anti-PD-1 Antibody/IL-18 Variant Immunocytokine… Advanced Solid Tumors Phase 1 · NCT06779851 Terminated
YB-1113 POI Phase 1 · NCT05494723 Not yet recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

DRUG holds $307.8M in cash and short-term investments and burns about $6.2M/quarter from operations, an estimated runway of 149.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 15 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when DRUG files for a raise →

👥 Who Owns DRUG

Insiders 17.7% Other 5%+ holders 30.9% Institutions 51.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
Ian McDonald 5%+ holder (13D) 1,396,665 30.87% 2024-11-04
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 1,284,324 28.39% 2026-03-31
Cormorant Asset Management, LP
Former 10% Owner
Insider 800,000 17.68% 2026-09-30
Blackrock Inc. Institution (13F) 651,794 14.41% 2026-09-30
Vestal Point Capital, LP Institution (13G, 5%+) 492,319 10.88% 2026-03-31
Braidwell LP Institution (13F) 483,822 10.69% 2026-09-30
Driehaus Capital Management, LLC Institution (13F) 445,221 9.84% 2026-09-30
Vivo Capital, LLC Institution (13F) 417,879 9.24% 2026-09-30
Point72 Asset Management, L.P. Institution (13F) 372,481 8.23% 2026-09-30
Adage Capital Partners GP L.L.C. Institution (13F) 324,800 7.18% 2026-09-30
Balyasny Asset Management LP Institution (13F) 304,561 6.73% 2026-09-30

Share count 4,524,087 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-04-28
filed 2026-04-30
Cormorant Asset Management, LP
Sale (S) 109,331 $89.50 950,000

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full DRUG picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DRUG and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.